Pipeline
Our Pipeline is comprised of Biologics, including the proprietary BEAT®MultispecificsTM platform, and one Cbl-b inhibitor small molecule, targeting the spectrum of immune cell engagement and indications across hematologic and solid tumors. If you are interested in exploring a partnership, Contact us.
Diversity of Immune Cell Engagement and Indications across Hematologic and Solid Tumors
Option for pipeline
| ASSETS | DESCRIPTION | INDICATION |
|---|---|---|
| DISCOVERY | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| GLOBAL RIGHTS |
|---|
(ABBV-2001)
Trispecific T-Cell Engager
(ISB 830)
ISB 830-X8
(STAR-0310)
Current Design
| ASSETS | DESCRIPTION | INDICATION |
|---|---|---|
| DISCOVERY | PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
|---|---|---|---|---|
| GLOBAL RIGHTS |
|---|
(ABBV-2001)
Trispecific T-Cell Engager
(ISB 830)
ISB 830-X8
(STAR-0310)
Oncology
Immunology
PRODUCTS
ASSETS
DESCRIPTION
CD38 x BCMA x CD3 TREAT™
Trispecific T-Cell Engager
INDICATION
Multiple Myeloma
PHASE
GLOBAL RIGHTS
PRODUCTS
ASSETS
ISB 880 (ALM27134)
DESCRIPTION
IL-1RAP antagonist mAb
INDICATION
Hidradenitis Suppurativa
PHASE
GLOBAL RIGHTS
PRODUCTS
ASSETS
Telazorlimab (ISB 830)
DESCRIPTION
OX40 antagonist mAb
INDICATION
Atopic Dermatitis
PHASE
GLOBAL RIGHTS
PRODUCTS
ASSETS
ISB 830-X8 (STAR-0310)
DESCRIPTION
OX40 antagonist mAb
INDICATION
Atopic Dermatitis
PHASE
GLOBAL RIGHTS
PRODUCTS
ASSETS
ISB 2301
DESCRIPTION
IMMUNITE™ NK-Cell Engager
INDICATION
Solid Tumors
PHASE
GLOBAL RIGHTS
PRODUCTS
ASSETS
DESCRIPTION
Cbl-b Inhibitor
INDICATION
Solid Tumors
PHASE
GLOBAL RIGHTS